<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04433052</url>
  </required_header>
  <id_info>
    <org_study_id>CPP-2020-1</org_study_id>
    <nct_id>NCT04433052</nct_id>
  </id_info>
  <brief_title>Clinical Value and Cost-effectiveness of a Personalized Prevention Program in Patients With High Risk Stable CHD</brief_title>
  <official_title>A Prospective Clinical Trial to Evaluate the Clinical Value and Cost-effectiveness of a Personalized Prevention Program in Patients With High Risk Stable Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective clinical study with two parts:

      PART A: a prospective biomarker-based risk screening study in coronary heart disease CHD
      patients PART B: a nested randomized clinical trial (RCT) in an enriched subpopulation of
      high-risk stable CHD patients

      PART A: 12 000 subjects with stable CHD

      PART B: 2000 subjects with high risk of CV events will be randomized to usual care (UC) or
      personal prevention program (PPP) i.e. 1000 subjects per arm.

      The main purpose of this study is to investigate the effectiveness of a PPP at reducing the
      risk in CHD patients identified to be at the highest risk for CVD death, non-fatal MI and
      heart failure events (HF). This study will follow outcomes of CHD patients over 3 years to
      determine the validity of a new risk screening method and the actual PPP. This study aims to
      prospectively demonstrate the value of preselected risk-screening biomarkers, and the
      clinical and economic efficacy of tailored prevention in high risk CHD patients. Furthermore,
      this study will demonstrate clinical value and provide prospective validation data for the
      digital tools (mobile application) utilized as part of the PPP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:

      PART A:

        -  To prospectively validate biomarkers in risk stratification among stable CHD patients

        -  To identify high-risk CHD patients for the subsequent RCT

      PART B

        -  To demonstrate, whether in high-risk CHD patients the PPP strategy results in decreased
           risk of cardiovascular (CV) events (CV death, nonfatal myocardial infarction (MI) or
           heart failure (HF) events) as compared to the local usual care (UC)

        -  To evaluate the health economic value of the PPP

      Primary Endpoint:

      • Effect of PPP on composite CV event (CV death, nonfatal MI, HF events) rate over 3 years
      follow-up
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study the effect of the PPP strategy in high-risk CHD patients on the risk of composite CV events (CV death, nonfatal MI or HF events) compared to the UC</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Effect of the PPP on composite CV event (CV death, nonfatal MI, HF events) rate over 3 years follow-up versus the rate of UC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the difference between PPP arm to the UC arm in</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Rates of specific CV events (CV death, nonfatal MI, HF events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the difference between PPP arm to the UC arm in</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Rates of secondary CV events (unstable angina, stroke and revascularizations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the difference between PPP arm to the UC arm in</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Treatment adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the health economic value of the PPP</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>A cost-effective analysis of PPP versus UC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker validation</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Association between separate risk biomarkers (CERT2, hs-TNI, proBNP , Cystatin C) or their score (CoroPredict) and CV composite and separate events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Personal prevention-program (PPP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be invited to return to the study site six times over a three year period to receive lifestyle coaching and exercise prescriptions. Eupropean Society of Cardiology/European Association of Preventive Cardiology (ESC/EAPC) -designed lifestyle counselling will be partially delivered by novel smartphone applications. Participants will also receive pharmaceutical treatment according to the ESC guideline for chronic coronary syndromes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care (UC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be referred back to usual care provided by their treating physicians. It is anticipated that physicians will treat these participants according to local usual medical practices. Patients randomized to UC group will not receive any treatment recommendations nor restrictions by the study investigators or nurses.
Randomized UC patients are invited to site visits twice over a three year period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>personal prevention</intervention_name>
    <description>Participants in the PPP arm will be invited to return to the study site six times over a three year period (at V02/day1, V03mo02, V04/mo6, V05/mo12,V06/mo18 and V07/mo36) to receive lifestyle coaching and exercise prescriptions. European Society of Cardiology/European Association of Preventive Cardiology (ESC/EAPC) -designed lifestyle counselling will be partially delivered by novel smartphone applications developed by the University of Hasselt and the University of Oulu.</description>
    <arm_group_label>Personal prevention-program (PPP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent form signed by the participants.

          2. Male or female aged 30 to 80 years on the day of screening.

          3. &gt; 50 stenosis in one more major coronary arteries in angiography or CT performed
             within the preceding one year or Myocardial infarction (type I, II) during the
             preceding year

        Exclusion Criteria:

          1. Hospitalization for acute coronary syndrome, myocardial infarct, stroke, coronary
             revascularization or acute heart failure within the preceding one month.

          2. Patients with NYHA class III-IV heart failure i.e. marked limitation in activity due
             to symptoms, comfortable only at rest

          3. Uncontrolled arrhythmias such as ventricular tachycardias

          4. Patients undergoing dialysis due to severe renal disease

          5. Diseases that severely disables exercising such as rheumatoid arthritis, neurological
             or orthopedic diseases.

          6. Known aplastic or hemolytic anemia

          7. Concomitant non-coronary disease such as malignancy that limits life expectancy to
             less than three years.

          8. Concurrent participation in another interventional study (medicinal, drug or medical
             device)

          9. Patients not able and/or willing to attend all scheduled visits and comply with all
             study procedures and use smartphone application
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reijo Laaksonen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tampere University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Marttila, MSc</last_name>
    <phone>+358407240771</phone>
    <email>hanna.marttila@tuni.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Juha Sinisalo, MD, PhD</last_name>
      <email>juha.sinisalo@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mehiläinen</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristiina Hotakainen, MD, PhD</last_name>
      <email>Kristina.Hotakainen@mehilainen.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Carelia Central Hospital</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Juha Hartikainen, MD, PhD</last_name>
      <email>juha.hartikainen@kuh.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Janne Hukkanen, MD, PhD</last_name>
      <email>janne.hukkanen@ppshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hellenic Red Cross Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konstantopoulio Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Patsilinakos Sotirios, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sismanoglion Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Biomedical Research Foundation of the Academy Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Constantinos Davos, MD, PhD</last_name>
      <email>cdavos@bioacademy.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Itolo Porto, MD, PhD</last_name>
      <email>italo.porto@unige.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrizio Montecucco, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Casilino Hospital Rome</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Turin</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gaetano de Ferrari, MD, PhD</last_name>
      <email>gaetanomaria.deferrari@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Bialystok</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Karol Kaminski, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Zbigniew Gasior, MD, PhD</last_name>
      <email>zgasior@ptkardio.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jagellonian University Medical College</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Lublin</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrzej Wysokinski, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus University</name>
      <address>
        <city>Toruniak</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Aldona Kubica, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Rafal Dabrowski, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital do Espirito Santo</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria-CHULN</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana Abreu, MD, PhD</last_name>
      <email>ananabreu@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University</investigator_affiliation>
    <investigator_full_name>Reijo Laaksonen</investigator_full_name>
    <investigator_title>Project Director</investigator_title>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>EU open access policy</ipd_description>
    <ipd_time_frame>opens 2 years after last study patient visit, open for 18 years until IPD deletion</ipd_time_frame>
    <ipd_access_criteria>Steering Committee decision, application needed</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

